KPC presence in pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 1086-1088

  Hagihara, Mao ^a,b   Crandon, Jared L ^a   Urban, Carl M ^c   Nicolaua, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b AICHI MEDICAL UNIVERSITY   (Japan)

^c NEW YORK HOSPITAL QUEENS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; CARBAPENEMASE 2; DORIPENEM; ERTAPENEM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; MICE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84872837222     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01748-12     Document Type: Article

References (12)

1. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J. 2004. Emergence of carbapenemresistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 ?-lactamases in New York City. Clin. Infect. Dis. 39:55-60.
2. Robledo IE, Aquino EE, Santé MI, Santana JL, Otero DM, León CF, Vázquez GJ. 2010. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob. Agents Chemother. 54:1354-1357.
3. Urban C, Bradford PA, Tuckman M, Segal-Maurer S, Wehbeh W, Grenner L, Colon-Urban R, Mariano N, Rahal JJ. 2008. Carbapenemresistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase ?-lactamases associated with long-term care facilities. Clin. Infect. Dis. 46:e127-e130.
4. Wolter DJ, Khalaf N, Robledo IE, Vázquez GJ, Santé MI, Aquino EE, Goering RV, Hanson ND. 2009. Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: Dissemination of KPC and IMP-18 ?-lactamases. Antimicrob. Agents Chemother. 53:1660-1664.
5. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP; Colombian Nosocomial Resistance Study Group. 2007. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing ?-lactamase. Antimicrob. Agents Chemother. 51: 1553-1555.
6. Bulik CC, Nicolau DP. 2011. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55:3002-3004.
7. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Bulik CC, Nicolau DP. 2010. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemaseproducing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 54: 4112-4115.
9. Crandon JL, Bulik CC, Nicolau DP. 2009. In vivo efficacy of 1-and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4352-4356.
10. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum-?-lactamase- producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob. Agents Chemother. 51:1481-1486.
11. Kim A, Banevicius MA, Nicolau DP. 2008. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob. Agents Chemother. 52:2497-2502.
12. Anderson KF, Lonsway DR, Rasheed JK, Biddle J, Jensen B, McDougal LK, Carey RB, Thompson A, Stocker S, Limbago B, Patel JB. 2007. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J. Clin. Microbiol. 45:2723-2725.